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Background: Since the 1970s, legislation has led to progress in tackling several air pollutants. We quantify the
annual monetary benefits resulting from reductions in mortality from the year 2000 onwards following the im-
plementation of three European Commission regulations to reduce the sulphur content in liquid fuels for vehicles.
Methods: We first compute premature deaths attributable to these implementations for 20 European cities in the
Aphekom project by using a two-stage health impact assessment method. We then justify our choice to only
consider mortality effects as short-term effects. We rely on European studies when selecting the central value of a
life-year estimate (E2005 86 600) used to compute the monetary benefits for each of the cities. We also conduct an
independent sensitivity analysis as well as an integrated uncertainty analysis that simultaneously accounts for
uncertainties concerning epidemiology and economic valuation. Results: The implementation of these regulations
is estimated to have postponed 2212 (95% confidence interval: 772–3663) deaths per year attributable to
reductions in sulphur dioxide for the 20 European cities, from the year 2000 onwards. We obtained annual
mortality benefits related to the implementation of the European regulation on sulphur dioxide of E2005 191.6
million (95% confidence interval: E2005 66.9–E2005 317.2). Conclusion: Our approach is conservative in restricting to
mortality effects and to short-term benefits only, thus only providing the lower-bound estimate. Our findings
underline the health and monetary benefits to be obtained from implementing effective European policies on air
pollution and ensuring compliance with them over time.
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Introduction
Since the 1970s, air quality has been one of the European Union’smajor areas of activity. Legislation has led to progress in tackling
several air pollutants, including sulphur dioxide (SO2), lead,
nitrogen oxide, carbon monoxide and benzene.1 However, other
pollutants such as ozone and particulate matter (PM) still require
attention.
Reductions in air pollutant levels have long been acknowledged to
lead to health benefits including reductions in the number of
medical consultations and hospital admissions for respiratory and
cardiovascular diseases, and of premature deaths.2,3 Therefore,
assessing the effectiveness of past regulations in terms of both
health impacts and avoided health care costs should provide useful
input to future regulations. Intervention studies constitute a relevant
way to check and help validate results obtained in non-intervention
studies, by focusing on the cause–effect relationship involved.
In addition, they limit the confounding of issues with respect to
other study designs by providing an exogenous change in
exposure.4,5
A recent review of air pollution interventions reported consistent
evidence that improved air quality following an intervention resulted
in public health improvements.6 Almost all intervention studies
assessing changes in SO2 and changes in health outcomes (such as
a US nationwide copper smelter strike in the 1960s,7 the 1990 Irish
coal ban,8 a 1990 regulation restricting the sulphur content of fuel in
Hong Kong9 or control regulations during the 2008 Beijing Summer
Olympic Games10) demonstrate beneficial health effects from
reducing SO2 emissions in terms of mortality, asthma visits and
cardio-respiratory hospital admissions.
Once the health benefits of an intervention study are estimated,
the economic benefits can be assessed and used in cost–benefit
analyses. Li et al.,11 for instance, quantified the health benefits of
curbing air pollution in Shanghai for two strategies aiming at
lowering PM10 and compared them with the investment costs.
They showed that the benefit-to-cost ratios exceed one in both
cases (1–5 for the power-sector strategy and 2–15 for the
industrial-sector strategy). Chestnut and Mills12 reconsidered the
US Acid Rain Program (Title IV of the 1990 Clean Air Act
Amendments) costs and benefits, providing updated estimates of
the health benefits. Controlling SO2 and nitrogen oxide emissions
led to total health and environmental benefits of more than US$100
billion annually in 2010, whereas costs were estimated at US$3
billion annually.
This paper focuses on the quantification of the monetary benefits
resulting from reductions in mortality following the implementation
of the European regulation to reduce the sulphur content in liquid
fuels. Indeed, European Council (EC) Directive 75/116/EEC limited
the sulphur compound content in gas oil to 0.3% by weight (and
0.5% in zones where SO2 was sufficiently low or insignificantly
coming from gas oil) as of 1 October 1980.13 Then, EC Directive
93/12/EEC introduced a regulation for the SO2 content permitted in
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certain gas oils and diesel fuels, excluding member states seeking
derogation14: 0.2% by weight as of 1 October 1994 and 0.05% by
weight as of 1 October 1996. The maximum sulphur content of
certain gas oil fuels for vehicles was further reduced by EC
Directive 98/70/EC to 0.035% for diesel fuels and 0.015% for
petrol as of 1 January 2000.15 Council Directive 99/32/EC
extended the 93/12/EEC Directive to cover certain liquid fuels
derived from petroleum and used by seagoing ships16 and specifies
the following as the permitted maximum SO2 content: 0.2% by mass
as of 1 July 2000 and 0.1% by mass as of 1 January 2008.
Our study used data from 20 cities included in the Aphekom
(Improving Knowledge and Communication for Decision Making
on Air Pollution and Health in Europe) project, a research
programme involving 60 scientists from 12 countries across
Europe. Aphekom’s objective was to provide new information and
tools to enable decision-makers to set more effective European,
national and local policies. To this end, it used traditional health
impact assessment (HIA) techniques as well as innovative methods
to explore the impact of air pollution on health in 25 European cities
totalling nearly 39 million inhabitants.
Methods
Background
Because the implementation dates for the EC directives on SO2 were
1994 (first stage), 1996 (second stage) and 2000 (third stage), city-
specific daily data on urban background (UB) SO2 concentrations,
temperature and humidity measures and numbers of deaths [all-
cause excluding external causes (ICD9: <800)] from 1990 to 2008
were collected using common guidelines based on the Apheis
project.17 Five cities were excluded due to missing data, leaving 20
cities from 11 countries in the analysis (see list in table 1).
However, not all countries complied with the implementation
dates as specified in the council directives, because of local deroga-
tions for instance. Hence, the number of stages implemented and
their corresponding implementation dates were not the same for
every city. The following 14 cities implemented all three stages of
the council directives: Athens, Bordeaux, Brussels, Dublin, Le Havre,
Lille, London, Lyon, Marseille, Paris, Rome, Rouen, Stockholm and
Strasbourg. The other six cities (Barcelona, Bilbao, Budapest,
Ljubljana, Toulouse and Vienna) only applied the last implementa-
tion stage, namely, Council Directive 99/32/EC. Our analysis assesses
the number of deaths from year 2000 onwards (after third imple-
mentation stage) compared with the pre-1993 period in all 20 cities.
The impacts of each of the three implementation stages on respira-
tory (ICD9: 460–519), cardiovascular (ICD9: 390–459) and total
(ICD9: [lt]800) mortality across the 20 cities have been reported
in another study.4
Computation of attributable premature deaths
We used a two-stage hierarchical modelling approach to assess the
mortality impact of the regulation up to implementation of the third
stage. In the first stage, data of each city were analysed separately,
whereas in the second stage, evidence across cities was combined
using meta-regression techniques. Briefly, for the first stage, city-
specific estimates were estimated from a Poisson regression model
linking mortality to UB SO2, adjusting for temperature, day of the
week, seasonality and time trend. Generalized additive models18
were used to control potential non-linearity between confounders
and mortality. The exposure variable used for UB SO2 was the
average of lags 1 and 2 (i.e. 1 and 2 days prior to the mortality
event).4 Additionally, dummy variables and their interaction with
UB SO2 were included in the model, depending on when council
directives were successfully implemented in each city. The second
stage of the modelling approach was designed to pool the city-
specific estimates of air pollution effects on health, using meta-
regression techniques.
SO2 effects on mortality in each city were combined in a meta-
analysis based on generalized least squares to provide overall
estimates. Variables representing potential effect modifiers (yearly
means of SO2, PM10 and temperature) were included in the
second-step regression models to account for city heterogeneity.
Details on the whole methodology have been previously
published,19 and models were run using R statistical software.20
The combined estimate of SO2 effect on mortality was then used
in the HIA to estimate the attributable number of premature deaths
(table 1).
Monetary assessment
Special features of the monetary assessment
By reducing UB SO2 levels in the 20 cities, the regulation has two
potential effects on mortality: short-term and long-term.
For acute (or short-term, ST) mortality effects, the number of
premature deaths avoided is generally computed through time-
series analyses and proportional hazard models. The gains in life
expectancy corresponding to each of these premature deaths can
be considered to be in the range of a few months, certainly lower
than 1 year.21
For chronic (or long-term, LT) mortality effects, the number of
premature deaths avoided is generally obtained via cohort studies
that monitor populations exposed to different levels of pollution.
One of the crucial issues is the magnitude of the gain in life
expectancy related to these premature deaths. Although no
definitive answer exists, a 10-year gain seems to be supported by
three types of evidence: medical, epidemiological and empirical from
past practice.21–24
Depending on whether the mortality effects are acute or chronic,
there are two possible ways to deal with the time that elapses
between a reduction in air pollution exposure due to the implemen-
tation of a regulation and the achievement of full health benefits.
In the ‘steady-state’ approach, the mortality effects corresponding
to two different levels of air pollution are assessed and the number of
premature deaths attributed to a change in air pollution exposure is
computed as the difference between the numbers of premature
Table 1 UB SO2 mean and standard deviation (SD) concentration
and number of attributable premature deaths for the 20 EU cities
(upper and lower 95% CI bounds)
City UB SO2 [mgm





95 CI 95 CI+
Athens (Greece) 38.97 26.96 507 177 842
Barcelona (Spain) 5.23 5.94 35 12 58
Bilbao (Spain) 17.46 7.19 14 5 24
Bordeaux (France) 7.22 5.06 18 6 29
Brussels (Belgium) 10.04 8.73 54 19 90
Budapest (Hungary) 29.07 19.56 390 136 647
Dublin (Ireland) 19.56 11.07 37 13 61
Le Havre (France) 23.38 28.26 23 8 38
Lille (France) 13.86 14.78 96 34 159
Ljubljana (Slovenia) 8.19 6.32 31 11 52
London (UK) 18.72 23.71 240 84 396
Lyon (France) 11.63 14.75 62 22 103
Marseille (France) 13.48 9.08 66 23 108
Paris (France) 12.16 10.88 314 110 519
Rome (Italy) 9.76 7.81 115 40 191
Rouen (France) 17.21 15.76 46 16 76
Stockholm (Sweden) 4.31 3.28 20 7 33
Strasbourg (France) 11.48 9.56 19 7 31
Toulouse (France) 21.67 15.85 35 12 58
Vienna (Austria) 8.92 11.70 90 31 148
Total – – 2212 772 3663
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deaths resulting from the respective steady states. This clear, simple
and informative approach is accurate for acute (or ST) mortality
effects, and provides an idea of the magnitude of the public health
problem for chronic (or LT) health effects.
In the ‘marginal (benefit)’ approach, the impact of a reduction in
today’s air pollution exposure on the future flow of mortality effects
is estimated. Reducing air pollution exposure via the implementa-
tion of a regulation in a given year does not produce all its chronic
(or LT) effects in the same year because these effects are
cumulative.25–28 This approach is appropriate for cost–benefit
analysis where chronic mortality effects are involved: the flow of
discounted future benefits can be properly compared with the
costs of the policy that generates these benefits.
Although the two approaches are similar for acute (ST) mortality
effects, they differ for chronic (LT) mortality effects due to the
latency period before the achievement of full mortality benefits
and the additional impact of discounting future monetary benefits.
In this paper, we consider mortality effects as ST effects only because
the health data analysis relies on time-series studies and not on
cohort studies. Because it takes a conservative standpoint, the
economic evaluation thus constitutes a lower bound of the
mortality effects of the regulation.
Economic values chosen
The valuation of mortality effects follows the standard valuation
procedure adopted in ExternE,29 New-Ext30 or CAFE,31 which
consists in using monetary values derived from stated preferences’
surveys, hence relying on preference-derived rather than market-
derived values. However, the choice of a proper economic value is
crucial because the gain in life expectancy related to a prevented
premature death differs according to whether it concerns those
affected by chronic or by acute effects (see previous text). Given
that we consider ST effects only, the gain in life expectancy
associated with each of the premature deaths is assumed to be
‘around 1 year’,21 so a value of a life year (VOLY) was chosen
here instead of a value of a statistical life.
Because the regulation effects are assessed in European cities, we
relied on European studies when selecting the VOLY. To allow for
the uncertainty pertaining in the economic valuation, we use a low, a
central and a high estimate of a VOLY. First, for the low estimate, we
take the recent results from the New Energy Externalities
Developments for Sustainability (NEEDS) program31 (based on a
3-month life expectancy gain with protesters and outliers deleted)
conducted in 10 European countries: E2005 40 000. Then, for the
high estimate, we choose E2005 133 200, the mean VOLY (annual
change 5:10 000 scenario) obtained in a study representative of the
European population, undertaken for the EC DG Research-funded
New-Ext30 project and used in CAFE cost–benefit analysis.21 Finally,
the arithmetic mean of high and low values provides the central
VOLY estimate: E2005 86 600.
Note that in the absence of reliable country-specific VOLY, the
valuation of mortality uses one common VOLY for all cities, because
we consider it to be ethically unacceptable to account for differences
across countries by ex-post wealth adjustments. Adjusting by gross
domestic product per capita, for instance, would lead to a fourfold
lower VOLY in Budapest than in Dublin.32
Results
Results on SO2 trends
Figure 1 shows a plot of yearly UB SO2 averages for 12 Aphekom
cities from 1990 to 2004 (see Henschel et al.33 for a detailed analysis
of the hourly SO2 pollution patterns for six of the cities). There is no
clear step change in UB SO2 concentrations after implementation of
the directives; rather, a gradual decline in SO2 levels is observed. The
decreasing levels over time are probably driven by the successful
implementation of various national and international regulations,
including the protocols under the Convention on Long-range
Transboundary Air Pollution,34 the installation of flue gas desul-
phurization units at power plants and political and economic
reforms in Eastern European countries, as well as reductions in
the sulphur content in fuel oil.35 The increase in SO2 levels in
Athens in 2002 and 2003 is mainly related to unfavourable winter
conditions but not to structural changes in the sources of emissions.
Moreover, rational behaviour in anticipation of an increase in the
cost of a tonne of SO2 (due to desulphurization) may have led some
major users of sulphurized fuel before 1994 to switch to natural gas
prior to the implementation of the regulation.
Results on HIA
Inference by eye36 did not provide evidence of changes in the slope
of the SO2–mortality dose–response curve after implementation of
the different legislations: 0.62 (95% CI: 0.3–0.95) before 1994, 0.71
(95% CI: 0.01–1.4) between 1994 and 1996, 0.64 (95% CI:
0.09–1.19) between 1996 and 2000 and 1.16 (95% CI: 0.67 to
3.02) after 2000. This is not altogether unexpected because it is
consistent with a linear dose–response curve down to very low con-
centrations. Over the study period, a decrease of 10 mgm3 in UB
SO2 levels was associated with a (pooled) decrease in daily all-cause
mortality of 0.53% (95% CI: 0.18–0.83). These findings were broadly
comparable with results from the APHEA multi-city study in
Europe: Katsouyanni et al.37 found that an increase of 50 mgm3
in SO2 was associated with an approximate increase of 3% for all-
cause mortality.
Applying the two-stage approach to city-specific mortality
incidence and SO2 level increases from pre- to post-intervention
period, the HIA analysis of the mortality data suggests an overall
2212 (95% CI: 772–3663) premature deaths avoided per year
associated with decreases in SO2 for 20 cities from year 2000
onwards (after third implementation stage) compared with the pre-
1993 period (see column labelled ‘Attributable premature deaths’ in
table 1 for results by city with the corresponding 95% CI). The lowest
number of postponed deaths attributable to the regulation is obtained
in Bilbao (14) and the highest in Athens (507).
Mortality benefits
Results and sensitivity analysis
Based on the number of premature deaths computed in table 1 and
the central estimate associated with a premature death avoided
(E86 600), the annual economic benefit related to the implementa-
tion of the EC regulations on SO2 amounts to E191.6 million (95%
CI: E66.9 million–E317.2 million). The detailed results as well as the
upper and lower 95% CI bounds for each city are given in table 2.
Bilbao obtains the lowest annual economic benefits, with E1.2
million (95% CI: E0.4 million–E2.1 million), and Athens obtains
the highest, with E43.9 million (95% CI: E15.3 million–E72.9
million).
We perform a sensitivity analysis specific to the economic
valuation by applying the low (E40 000) and high (E133 200)
estimates of the VOLY to the number of premature deaths
provided by the epidemiological computations. Results are
presented in table 2 and represent a range of monetary benefits
(low and high) for the number of premature deaths as well as for
the related upper and lower 95% CI bounds.
Uncertainty analysis
Uncertainty analysis simultaneously accounts for uncertainties
concerning epidemiology and economic valuation through an
integrated approach. The results of the HIA and the economic
values are treated as random variables with specified distributions
of probability. Monte Carlo simulations are used to propagate the
Economic valuation of a regulation on SO2 3 of 6






uncertainty in the numbers of premature deaths and the VOLY, by
drawing random samples from the distributions. Each draw
generates an estimate of the annual monetary benefits, and a
sufficient number of draws makes it possible to characterize the
distribution of these monetary benefits.38
A normal distribution is used to characterize the spread of the
mortality data, defined in terms of its mean and standard deviation.
This choice relies on the assumptions and data obtained by the HIA.
A triangular distribution is used for the VOLY, defined in terms of a
modal central value, a maximum and a minimum. The triangular
distribution is typically used when knowledge of the variable is more
subjective than objective.
Once these probability distributions are defined, the model is run
using 10 000 Monte Carlo samples and provides probabilized
Figure 1 Plot of yearly UB SO2 averages of 12 Aphekom cities* from 1990 to 2004 (*of the nine French cities involved in the project, only
Paris is included here)
Table 2 Annual monetary benefits for the 20 EU from 2000 onwards compared with the pre-1993 period (central, low and high estimates of
the number of premature deaths and of the upper and lower 95% CI bounds)
City Monetary valuation (million E 2005)
Central estimate (VOLY=E86600) Low estimate (VOLY=E40000) High estimate (VOLY=E133200)
Benefits 95 CI 95 CI+ Benefits 95 CI 95 CI+ Benefits 95 CI 95 CI+
Athens 43.9 15.3 72.9 20.3 7.1 33.7 67.5 23.6 112.2
Barcelona 3.0 1.0 5.0 1.4 0.5 2.3 4.7 1.6 7.7
Bilbao 1.2 0.4 2.1 0.6 0.2 1.0 1.9 0.7 3.2
Bordeaux 1.6 0.5 2.5 0.7 0.2 1.2 2.4 0.8 3.9
Brussels 4.7 1.6 7.8 2.2 0.8 3.6 7.2 2.5 12.0
Budapest 33.8 11.8 56.0 15.6 5.4 25.9 51.9 18.1 86.2
Dublin 3.2 1.1 5.3 1.5 0.5 2.4 4.9 1.7 8.1
Le Havre 2.0 0.7 3.3 0.9 0.3 1.5 3.1 1.1 5.1
Lille 8.3 2.9 13.8 3.8 1.4 6.4 12.8 4.5 21.2
Ljubljana 2.7 1.0 4.5 1.2 0.4 2.1 4.1 1.5 6.9
London 20.8 7.3 34.3 9.6 3.4 15.8 32.0 11.2 52.7
Lyon 5.4 1.9 8.9 2.5 0.9 4.1 8.3 2.9 13.7
Marseille 5.7 2.0 9.4 2.6 0.9 4.3 8.8 3.1 14.4
Paris 27.2 9.5 44.9 12.6 4.4 20.8 41.8 14.7 69.1
Rome 10.0 3.5 16.5 4.6 1.6 7.6 15.3 5.3 25.4
Rouen 4.0 1.4 6.6 1.8 0.6 3.0 6.1 2.1 10.1
Stockholm 1.7 0.6 2.9 0.8 0.3 1.3 2.7 0.9 4.4
Strasbourg 1.6 0.6 2.7 0.8 0.3 1.2 2.5 0.9 4.1
Toulouse 3.0 1.0 5.0 1.4 0.5 2.3 4.7 1.6 7.7
Vienna 7.8 2.7 12.8 3.6 1.2 5.9 12.0 4.1 19.7
Total 191.6 66.9 317.2 88.5 30.9 146.5 294.6 102.8 487.9
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distributions of the product of the annual number of postponed
deaths and the VOLY, representing the annual mortality benefits.
Figure 2 shows the distribution of the annual mortality benefits for
the 20 EU cities that implemented the third implementation stage.
The mean is E191.44 million, and the empirical 95% CI is E57.5
million–E363.6 million. This range is slightly wider than the range
obtained previously because it accounts jointly for epidemiological
and economic uncertainties.
Discussion
Our findings underline the health and monetary benefits obtained
from drafting and implementing effective EU policies on air
pollution, and by ensuring compliance with them over time. They
show a marked and sustained reduction in ambient SO2 levels over
time in the 20 cities. Some of this decrease is attributable to the
implementation of Council Directive 93/12/EEC and its amended
version, and we estimate that some 2200 premature deaths were
prevented annually, valued at E192 million.
We should bear in mind that SO2 emissions have long been
acknowledged to also generate direct monetary effects on
morbidity39 and crops,40,41 as well as more intangible effects on
the environment42,43 that were not assessed in our study. Chestnut
and Mills,12 when assessing the US Acid Rain Program benefits,
account for effects on ST and LT human health benefits as well as
visibility, natural resources and deposition on materials. This paper
thus only partially evaluates the full economic benefits of the
regulation, as it limits itself to ST mortality effects.
Moreover, although the regulation on SO2 has two potential
effects on mortality, ST and LT, we take a conservative standpoint,
restricting mortality effects to ST effects and consequently valuing
them with a VOLY instead of a value of a statistical life. The
economic evaluation thus constitutes a lower bound of the
mortality gains of the regulation.
Finally, we should acknowledge that the benefits of SO2 reduction
may also have arisen from reductions in other pollutants. SO2 was
not the only pollutant to decrease over the period studied, black
smoke, for instance, also decreases, and we cannot distinguish the
separate effects of the various pollutants. Thus, care should be taken
in future work not to double count by repeating the analysis on
other pollutants and totalling the results. Moreover, the concentra-
tion–response functions used to assess the mortality impact are
derived from observational studies that only provide evidence for
associations, and causality cannot be inferred because other (non-
pollution) factors cannot be ruled out.
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Keypoints
 We quantify the monetary benefits resulting from reductions
in mortality following the implementation of the European
regulation to reduce the sulphur content in liquid fuels.
 We find a marked and sustained reduction in ambient SO2
levels over time for 20 European cities, and we estimate that
some 2200 premature deaths were prevented annually,
valued at E192 million.
 We perform both sensitivity and uncertainty analyses and
obtain a slightly wider range for the latter, as it jointly
accounts for epidemiological and economic uncertainties.
Figure 2 Probability distribution of the annual monetary benefits for the 20 EU cities (generated from Monte Carlo sampling over 10000
iterations)
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 Our findings underline the health and monetary benefits
obtained from drafting and implementing effective EU
policies on air pollution, and by ensuring compliance with
them over time.
 By assessing the effectiveness of past regulations in terms of
both health impacts and avoided health costs, we provide
useful input to future regulations.
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